According to the Complaint, Aratana Therapeutics, Inc. is a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats.

This action stems from a proposed transaction announced on April 26, 2019, pursuant to which Aratana Therapeutics, Inc. will be acquired by Elanco Animal Health Incorporated.

On April 26, 2019, Aratana’s Board of Directors caused the Company to enter into an agreement and plan of merger with Elanco. Pursuant to the terms of the Merger Agreement, Aratana’s stockholders will receive 0.1481 shares of Elanco stock and one contingent value right for each share of Aratana common stock they own.

On May 30, 2019, Defendants filed a Registration Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.

This case was voluntarily dismissed on September 11, 2019.